Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Ono Ties Up with AI Startup twoXAR on Drug Discovery
March 19, 2019
- 9 Month Cost-Effectiveness Analysis Possible If Companies Are Well-Prepared: Crecon Official
March 19, 2019
- Employee Sues Bayer Japan for Emotional Distress over Xarelto Scandal
March 19, 2019
- Hitachi Chemical Aspires to World’s No. 1 Regenerative Medicine CMO by Securing Bases in US, Europe through M&As
March 19, 2019
- Entrectinib Filed in Japan for ROS1 Lung Cancer: Chugai
March 18, 2019
- Alfresa Seeks to Expand Foothold in China via Tie-Up with 2nd Largest Drug Wholesaler
March 18, 2019
- Drug Makers, Wholesalers Establishing Supervisory Divisions as Detailing Guidelines Rollout Nears
March 15, 2019
- Synthetic Rubber Form of Rivastach/Exelon Patch Approved: Ono/Novartis
March 15, 2019
- Aricept Generics Earn Lewy Body Dementia Indications
March 14, 2019
- Fujifilm Going Full Throttle in CDMO Biz with Buyout of Biogen Unit
March 13, 2019
- Urief Authorized Generics Now Available: Daiichi Sankyo Espha
March 13, 2019
- FDA Accepts NDA for Insomnia Med Lemborexant, Target Date Set for Dec. 27
March 13, 2019
- Vadadustat Demonstrates Efficacy, Safety in 4 PIII Studies for Renal Anemia: Mitsubishi Tanabe
March 13, 2019
- Galderma Delivers in PIIb Atopic Dermatitis Study for Nemolizumab, Originated by Chugai
March 12, 2019
- Vimpat Dry Syrup Now Available: Daiichi Sankyo, UCB
March 12, 2019
- BMS, Ono Submit Additional Study Data on Orencia for Prevention of Structural Damage to Joints
March 12, 2019
- Fujifilm Toyama Chemical, Sanwa Kagaku Tie Up for Lantus Biosimilar Promotion
March 12, 2019
- UCB, Otsuka to End Copromotion Deal for E Keppra in Japan in 2020
March 12, 2019
- Daiichi Sankyo Espha Launches Authorized Iressa Generic, Introducing AI to Respond to Inquiries
March 12, 2019
- Entyvio Shows Superiority to Humira in PIIIb Study for UC: Takeda
March 12, 2019
ページ
Chugai Pharmaceutical’s Duchenne muscular dystrophy (DMD) gene therapy Elevidys has finally reached the Japanese market after months of safety reviews…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…